Cardiome Pharma Corp. (CRME) Forms $1.46 Double Bottom; Mainstay Definedterm Municipal Opportunities Fund (MMD)’s Sentiment Is 1.17

The stock decreased 0.68% or $0.13 during the last trading session, reaching $19.01. About 29,384 shares traded. MainStay DefinedTerm Municipal Opportunities Fund (MMD) has declined 0.25% since February 2, 2017 and is downtrending. It has underperformed by 16.95% the S&P500.

Cardiome Pharma Corp. (CRME) formed double bottom with $1.33 target or 9.00% below today’s $1.46 share price. Cardiome Pharma Corp. (CRME) has $48.49M valuation. The stock decreased 0.68% or $0.01 during the last trading session, reaching $1.46. About 27,510 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 11.02% since February 2, 2017 and is downtrending. It has underperformed by 27.72% the S&P500.

Analysts await Cardiome Pharma Corp. (NASDAQ:CRME) to report earnings on March, 6. They expect $-0.19 earnings per share, down 5.56% or $0.01 from last year’s $-0.18 per share. After $-0.20 actual earnings per share reported by Cardiome Pharma Corp. for the previous quarter, Wall Street now forecasts -5.00% EPS growth.

Among 6 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cardiome Pharma Corp has $12.50 highest and $3.50 lowest target. $8.10’s average target is 454.79% above currents $1.46 stock price. Cardiome Pharma Corp had 15 analyst reports since August 11, 2015 according to SRatingsIntel. Mackie upgraded it to “Speculative Buy” rating and $8.60 target in Friday, May 6 report. The rating was reinitiated by Canaccord Genuity on Monday, July 17 with “Buy”. Canaccord Genuity maintained Cardiome Pharma Corp. (NASDAQ:CRME) rating on Wednesday, November 15. Canaccord Genuity has “Buy” rating and $5 target. The firm earned “Hold” rating on Wednesday, October 12 by Mackie. The stock has “Buy” rating by Zacks on Tuesday, August 11. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) earned “Buy” rating by LB Securities on Friday, August 14. The company was downgraded on Wednesday, August 26 by Zacks. The firm has “Buy” rating given on Wednesday, November 22 by H.C. Wainwright. The company was initiated on Thursday, December 22 by Leerink Swann. Canaccord Genuity maintained the stock with “Buy” rating in Monday, August 21 report.

Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.26, from 0.83 in 2017Q2. It increased, as 2 investors sold Cardiome Pharma Corp. shares while 9 reduced holdings. 7 funds opened positions while 5 raised stakes. 13.54 million shares or 10.92% less from 15.20 million shares in 2017Q2 were reported. Pnc invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Scotia Cap Inc reported 19,120 shares. 600,625 are owned by Alphaone Investment Services Ltd Liability Corp. Putnam Invests Limited Liability holds 0.02% or 3.09M shares. Ardsley Advisory Prtn owns 36,200 shares for 0.01% of their portfolio. Knott David M reported 134,478 shares. Toronto Dominion Bancshares invested in 0% or 84 shares. Jpmorgan Chase owns 158,697 shares or 0% of their US portfolio. Savings Bank Of Montreal Can reported 1,004 shares. Grp One Trading Limited Partnership stated it has 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Renaissance Technology Ltd Co accumulated 411,413 shares or 0% of the stock. Morgan Stanley invested 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Geode Mgmt Lc invested in 0% or 18,731 shares. Bancshares Of Nova Scotia holds 10 shares or 0% of its portfolio. Citadel Limited Company invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME).